Sotac Pharmaceuticals

Sotac Pharmaceuticals Shares Outstanding

The The number of shares of Sotac Pharmaceuticals (SOTAC.NS) as of Oct 28, 2026 is 11.05 M. In the previous year, The number of shares was 11.05 M — a change of 0.00% (lower).

Shares Outstanding

11.05 M

YoY

0.00%

Last updated:

In 2025, Sotac Pharmaceuticals had 11.05 M outstanding stocks, a 0.00% change from the 11.05 M stocks in the previous year.

The Sotac Pharmaceuticals Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2020
11.05 M INR
Jan 1, 2021
11.05 M INR
Jan 1, 2022
11.05 M INR
Jan 1, 2023
11.05 M INR
Jan 1, 2024
11.05 M INR
Jan 1, 2025
11.05 M INR
The Sotac Pharmaceuticals Shares Outstanding history
YEARShares OutstandingYoY
11.05 M0.00%
11.05 M0.00%
11.05 M0.00%
11.05 M0.00%
11.05 M0.00%
11.05 M—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sotac Pharmaceuticals Number of shares

Sotac Pharmaceuticals shares outstanding

The number of shares of Sotac Pharmaceuticals was 11.05 M in 2025. This indicates how many shares Sotac Pharmaceuticals is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
11.05 M Stocks
Jan 1, 2021
11.05 M Stocks
Jan 1, 2022
11.05 M Stocks
Jan 1, 2023
11.05 M Stocks
Jan 1, 2024
11.05 M Stocks
Jan 1, 2025
11.05 M Stocks

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating Sotac Pharmaceuticals's Shares Outstanding

Sotac Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Sotac Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Sotac Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Sotac Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Sotac Pharmaceuticals stock

The number of shares of Sotac Pharmaceuticals is 11.05 M in 2025.

The number of shares of Sotac Pharmaceuticals changed from 11.05 M to 11.05 M, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of shares Sotac Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Other — Sotac Pharmaceuticals

Shares OutstandingSupply ChainNet Debt per ShareAssets per Share

All Key Metrics — Sotac Pharmaceuticals